| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Di-tert-butyl diisopropylphosphoramidite does not have a defined biological target as it is a chemical reagent for oligonucleotide synthesis. Its role is to serve as a building block for introducing tert-butyl-protected phosphate groups into biomolecules. The compound is used in the phosphorylation of biomolecules and the synthesis of phosphoramidate-linked glycoconjugates.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, this phosphoramidite monomer is used for the phosphorylation of biomolecules and the synthesis of oligonucleotides. The compound is a versatile reagent for introducing tert-butyl-protected phosphate groups. It can be used in the synthesis of phosphoramidate-linked glycoconjugates. The resulting modified biomolecules can be used in various research applications.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a chemical synthesis reagent rather than a bioactive molecule. Oligonucleotides and other biomolecules synthesized using this reagent can be delivered into cells for various functional studies. The tert-butyl-protected phosphate groups introduced by this reagent can be deprotected to yield phosphate-containing biomolecules for cellular studies.
|
| Enzyme Assay |
The standard procedure for using this phosphoramidite involves its use in oligonucleotide synthesis or phosphorylation reactions. The compound is typically used as a reagent in organic synthesis. For oligonucleotide synthesis, it is used as a phosphoramidite monomer in solid-phase synthesis. For phosphorylation, it is used to introduce tert-butyl-protected phosphate groups into biomolecules.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to this phosphoramidite as it is a chemical synthesis reagent. Oligonucleotides and other biomolecules synthesized using this reagent can be evaluated in cell culture experiments. Typical protocols include transfection of modified oligonucleotides into mammalian cell lines and assessment of their biological activity, stability, and functional effects.
|
| Animal Protocol |
Di-tert-butyl diisopropylphosphoramidite is not administered to animals as it is a chemical reagent for synthesis. Oligonucleotides and other biomolecules synthesized using this reagent may be evaluated in animal models for therapeutic applications. Typical studies involve administration of modified oligonucleotides to mice or rats via various routes.
|
| ADME/Pharmacokinetics |
As a chemical reagent, this compound does not have established pharmacokinetic properties. Oligonucleotides and other biomolecules containing phosphate groups introduced using this reagent may have their own pharmacokinetic properties depending on their structure and modifications. The compound itself is not intended for therapeutic use.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent【37†37】. The compound is typically stored refrigerated (0-10°C) under inert gas【37†37】. As a chemical reagent, it should be handled with care to avoid exposure.
|
| Additional Infomation |
Di-tert-butyl diisopropylphosphoramidite is a research-grade chemical supplied for oligonucleotide synthesis and phosphorylation applications. It is not an approved pharmaceutical and has no clinical trial history. The compound is a phosphoramidite monomer used in the preparation and synthesis of oligonucleotides. This product is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C14H32NO2P
|
|---|---|
| Molecular Weight |
277.39
|
| Exact Mass |
277.217
|
| CAS # |
137348-86-8
|
| PubChem CID |
853005
|
| Appearance |
Liquid
|
| Density |
0.879
|
| Boiling Point |
252.2±9.0 °C at 760 mmHg
|
| Melting Point |
85-90ºC 0.2 mm Hg(lit.)
|
| Flash Point |
106.4±18.7 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.444
|
| LogP |
5.72
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
18
|
| Complexity |
217
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(N(C([H])(C([H])([H])[H])C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])(OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
YGFLCNPXEPDANQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H32NO2P/c1-11(2)15(12(3)4)18(16-13(5,6)7)17-14(8,9)10/h11-12H,1-10H3
|
| Chemical Name |
N-[bis[(2-methylpropan-2-yl)oxy]phosphanyl]-N-propan-2-ylpropan-2-amine
|
| Synonyms |
Di-tert-butyl diisopropylphosphoramidite
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6050 mL | 18.0252 mL | 36.0503 mL | |
| 5 mM | 0.7210 mL | 3.6050 mL | 7.2101 mL | |
| 10 mM | 0.3605 mL | 1.8025 mL | 3.6050 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
